Year: 2025
Type: article
Abstract: BACKGROUND: Patients with advanced cancer often have type 2 diabetes mellitus (T2DM) and are on multiple medications that affect glycaemic control. Patients can have pre‑existing diabetes or treatment- and glucocorticoid-induced hyperglycaemia. Optimal management of glycaemic control differs at varying stages of life and depends on overall goals of care. OBJECTIVE: This article summarises the evidence-based management of T2DM in patients with advanced cancer, including management of glucocorticoid-induced hyperglycaemia, and appropriate targets for glycated haemoglobin (HbA1c). DISCUSSION: T2DM often co-exists in patients with advanced cancer. Management is aimed at reducing the complications of hyperglycaemia and hypoglycaemia, and maximising quality of life. Interventions and treatments need to be balanced against quality of life and prognosis.
Authors: Aanjanee Weerasinghe, Phillip Good, Claire Stokes, Jones Chen, Taylan Gurgenci
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4412957402